- Trouble de l’Érection
- Published:
Apomorphine, systèmes dopaminergiques centraux et contrôle de l’érection
Apomorphine, central dopaminergic pathways and control of penile erection
Andrologie volume 12, pages 156–166 (2002)
Résumé
L’érection est un mécanisme vasculotissulaire provoqué par la relaxation des fibres musculaires lisses du pénis et des artères qui l’irriguent. L’érection est contrôlée par le système nerveux autonome, les voies parasympathiques étant proérectiles et les voies sympathiques antiérectiles.
Au cours des dernières années, les nombreuses données fondamentales élucidant les mécanismes locaux de l’érection ont permis de proposer des traitements des dysfonctions érectiles par des médicaments à action périphérique. Ces produits permettent soit de provoquer une érection, ils sont alors efficaces seuls, soit de potentialiser une érection.
Dans un environnement sexuellement stimulant, l’érection est provoquée par une modification de l’équilibre des effets antiérectiles du système sympathique et des effets proérectiles du système parasympathique. Les voies sympathiques et parasympathiques naissent de la moelle épinière. Le système nerveux central agit sur la moelle épinière pour contrôler et modifier cet équilibre sympathique-parasympathique. La dopamine est un neuromédiateur du système nerveux central agissant sur le comportement sexuel et sur les noyaux centaux contrôlant le tractus génital chez le mâle. Les taux de dopamine augmentent dans plusieurs noyaux centraux (amygdale, aire préoptique médiane) pendant l’activité sexuelle chez le rat. Les agonistes dopaminergiques à action centrale comme l’apomorphine (agoniste D1/D2) provoquent l’érection chez l’homme, le singe et le rat. Chez le rat, les effets proérectiles de l’apomorphine sont dus à sa fixation sur des récepteurs de type D2 dans le noyau paraventriculaire de l’hypothalamus (PVN), et seraient régulés par la testostérone. Des investigations cliniques récentes ont mis en avant les avantages de l’utilisation de l’apomorphine pour traiter les patients souffrant de dysfonctions érectiles. Une molécule à action centrale comme l’apomorphine pourrait réorganiser l’équilibre sympathique-parasympathique, conduisant à un recrutement adapté des voies nerveuses vers le pénis.
Abstract
Relaxation of penile erectile tissue and increased blood flow in the penile arteries are the two basic local mechanisms of erection. Relaxation is elicited by several agents released by the nerve terminals of sacral parasympathetic pathways (nitric oxide [NO] and vasoactive intestinal polypeptide [VIP]) and endothelial cells. The increased activity of sacral parasympathetic pathways leads to erection. Other molecules (e.g. noradrenaline) released by the nerve endings of sympathetic pathways contract the penile tissue and arteries. A decrease in sympathetic pathway activity can therefore lead to erection. A better understanding of the local mechanisms of penile erection has led to the production of compounds designed to treat erectile dysfunction via a peripheral target. Such compounds are recognised as initiators if they elicit erectionper se or as conditioners if they potentiate a mechanism already present.
The central control of penile erection plays an important role in the optimal functioning of the erectile process. Sympathetic and parasympathetic nerves to the penis originate in the spinal cord. In a sexually relevant context, it is likely that a shift of the balance between sympathetic and parasympathetic activities causes erection. This shift is controlled at the spinal cord level by information from the periphery (reflex pathways) and from supraspinal nuclei. Recent experiments have focused on supraspinal nuclei present in the brainstem, pons, and hypothalamus that directly project onto the sacral spinal cord. Pharmacological approaches have revealed an important role for central dopamine in the control of sexual behavior and the genital tract in males. Central dopamine can therefore regulate both sympathetic and parasympathetic pathways. Levels of DA and its metabolites increase in several brain structures during sexual activity. DA agonists, e.g. the D1/D2 agonist apomorphine, affect the sexual behavior, erection and ejaculation in a variety of animal species and in humans. Recent clinical investigations have revealed the benefits of the use of apomorphine in patients suffering from erectile dysfunction. Compounds acting centrally, such as apomorphine, can contribute to reorganize the activity of sympathetic and parasympathetic outflows leading to an appropriate recruitment of the autonomic pathways to the genital tract.
Références
ANDERSSON, K.E.: Pharmacology of penile erection. Pharmacol. Rev., 2001, 53: 417–450.
ANDERSSON K.E., GEMALMAZ H., WALDECK K., CHAPMAN T.N., TUTTLE J.B., STEERS W.D.: The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat. J. Urol., 1999, 161: 1707–1712.
ANDERSSON K.E., WAGNER G.: Physiology of penile erection. Physiol. Rev., 1995, 75: 191–236.
AOKI, H., FUJIOKA T., MATSUZAKA J., KUBO T., NAKAMURA K., YASUDA N.: Suppression by prolactin of the electrically induced erectile response through its direct effect on the corpus cavernosum penis in the dog. J. Urol., 1995, 154: 595–600.
ARGIOLAS A., MELIS M.R., MAURI A., GESSA G.L.: Paraventricular nucleus lesion prevents yawning and penile erection induced by apomorphine and oxytocin but not by ACTH in rats. Brain Res., 1987: 421, 349–352.
BAGGIO G., FERRARI F.: The role of dopaminergic receptors in the behavioral effects induced by lisuride in male rats. Psychopharmacol., 1983, 80: 38–42.
BALOGH S., HENDRICKS S.E., KANG J.: Treatment of fluoxetine-induced anorgasmia with amantadine. J. Clin. Psychiatry, 1992, 53: 212–213.
BARALDI M., BENASSI-BENELLI A., BERNABEI M.T., CAMERONI R., FERRARI F., FERRARI P.: Apocodeine-induced stereotypies and penile erection in rats. Neuropharmacology, 1979, 18: 165–169.
BAZZETT T.J., EATON R.C., THOMPSON J.T., MARKOWSKI, V.P., LUMLEY, L.A., HULL E.M.: Dose dependent D2 effects on genital reflexes after MPOA injections of quinelorane and apomorphine. Life Sci., 1991, 48: 2309–2315.
BEN-JONATHAN N., HNASKO R.: Dopamine as a prolactin (PRL) inhibitor Endocrine Rev., 2001, 22: 724–763.
BENASSI-BENELLI A., FERRARI F., PELLEGRINI-QUARANTOTTI B.: Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch. Int. Pharmacodyn. Ther., 1979, 242: 241–247.
BENASSI-BENELLI A., FERRARI F.: Activation with N-n-propyl-norapomorphine (NPA) of the male rat copulatory behavior. Experientia, 1979, 35: 645–646.
BERENDSEN H.H.G., GOWER A.J.: Opiate-androgen interactions in drug-induced yawning and penile erections in the rat. Neuroendocrinology, 1986, 42: 185–190.
BERNABE J., RAMPIN O., SACHS B.D., GIULIANO F.: Intracavernous pressure during erection in rats: an integrative approach based on telemetric recording. Am. J. Physiol., 1999, 276: 441–449.
BITRAN D., HULL E. M.: Pharmacological analysis of male sexual behavior. Neurosci. Biobehav. Rev., 1987, 11: 365–389.
BITRAN D., THOMPSON J.T., HULL E.M., SACHS B.D.: Quinelorane (LY 163502), a D2 dopamine receptor agonist, facilitates seminal emission, but inhibits penile erection in the rat. Pharmacol. Biochem. Behav., 1989, 34: 453–458.
BLIN O., SCHWERTSCHLAG U.S., SERRATRICE G.: Painful clitoral tumescence during bromocriptine therapy. Lancet, 1991, 337: 1231–1232.
BOWERS M.B., VAN WOERT M., DAVIS L.: Sexual behavior during L-DOPA treatment for Parkinsonism. Am. J. Psychiatry, 1971, 127: 1691–1693.
BROWN E., BROWN G.M., KOFMAN O., QUARRINGTON B.: Sexual function and affect in Parkinsonian men treated with L-DOPA. Am. J. Psychiatry, 1978, 135: 1552–1555.
BUVAT J., LEMAIRE A., BUVAT-HERBAUT M., FOURLINNIE, J.C., RACADOT A., FOSSATI P.: Hyperprolactinemia and sexual function in men. Horm. Res., 1985, 22, 196–203.
CHEN K.K., CHAN J.Y., CHANG L.S.: Dopaminergic neurotransmission at the paraventricular nucleus of the hypothalamus in central regulation of penile erection in the rat. J. Urol., 1999, 162: 237–242.
CHRISTMAS T.J., KEMPSTER P.A., CHAPPLE C.R. et al.: Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet, 1988, 2: 1451–1453.
CLARK J.T., SMITH E.R., STEFANIK M.L., ARNERIC S.P., LONG J.P., DAVIDSON J.M.: Effects of a novel dopamine-receptor agonist, RDS-127 (2-N,N-di-n-propylamino-4,7-dimethoxyindane), on hormone levels and sexual behavior in the male rat. Physiol. Behav., 1982, 29: 1–6.
CLARK J.T., STEFANIK M.L., SMITH E.R., DAVIDSON J.M.: Further studies on alterations in male rat copulatory behavior induced by the dopamine-receptor agonist RDS-127. Pharmacol. Biochem. Behav., 1983, 19: 781–786.
CLARK J.T., PEROUTKA S.J., CIARANELLO R.D., SMITH E.R., DAVIDSON J.M.: Central effects of RDS-127: sexual behavior after intracerebroventricular administration and in vitro receptor binding studies. Behav. Brain Res., 1985, 18: 251–260.
COOPER A.J.: Bromocriptine in impotence. Lancet. 1977, 2: 8037, 567.
COURTY E., DURIF F., ZENUT M., COURTY P., LAVARENNE J.: Psychiatric and sexual disorders induced by apomorphine in Parkinson’s disease. Clin. Neuropharmacol., 1997, 20: 140–147.
DANJOU P., LACOMBLEZ L., WAROT D., PUECH A.J.: Assessment of erectogenic drugs by numeric plethysmography, J. Pharm. Meth., 1989, 21: 61–69.
DANJOU P., ALEXANDRE L., WAROT D., LACOMBLEZ L., PUECH A.J.: Assessment of erectogenic properties of apomorphine and yohimbine in man. Brit. J. Clin. Pharmacol., 1988, 26: 733–739.
DE ROSA M., COLAO A., DI SARNO A. et al.: Treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. J. Endoccrinol., 1998, 138: 286–293.
DOHERTY P.C., BAUM M.J., TODD R.B.: Effects of chronic hyperprolactinemia on sexual arousal and erectile function in male rats. Neuroendocrinology, 1986, 42: 368–375.
DOHERTY P.C., WU DE, MATT K.S.: Hyperprolactinemia preferentially inhibits erectile function in adrenalectomized male rats. Life Sci., 1990, 47: 141–148.
DOHERTY P.C., WISLER P.A.: Stimulatory effects of quinelorane on yawning and penile erection in the rat. Life Sci., 1994, 54: 507–514.
DRAGO F., PELLEGRINI-QUARANTOTTI B., SCAPAGNINI U., GESSA G.L.: Short-term endogenous hyperprolactinemia and sexual behavior of male rats. Physiol. Behav., 1981, 26: 277–279.
DU, J., LORRAIN D.S., HULL E.M.: Castration decreases extracellular, but increases intracellular, dopamine in medial preoptic area of male rats. Brain Res., 1998, 782, 11–17.
DULA E., KEATING W., SIAMI P.F., EMDONDS A., O’NEIL J., BITTLER S., and the APO Study Group: Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology, 2000, 56: 130–135.
EATON R.C., MARKOWSKI V.P., LUMLEY L.A., THOMSON J.T., MOSES J., HULL E.M.: D2 receptors in the paraventricular nucleus regulate genital responses and copulation in male rats. Pharmacol. Biochem. Behav., 1991, 39 177–181.
ELABBADY A., HASSOUNA M.M., ELHILALI M.: Apomorphine versus mating behavior in testing erectile capabilities of diabetic rats. Urology, 1995, 45: 715–719.
FAGAN T.C., BUTTLER S., MARBURY T., TAYLOR A., EDMONDS A. and the SL Apo Study Group: Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am. J. Cardiol., 2001, 88: 760–766.
FERRARI F., BAGGIO G.: Potentiation of the aphrodisiac effect of N-n-propyl-norapomorphine by naloxone. Eur. J. Pharmacol., 1982, 81: 321–326.
FERRARI F.: Sexual excitement and stretching and yawning induced by B-HT 920. Pharmacol. Res. Comm., 1985, 17: 557–564.
FERRARI F., GIULIANI D.: Behavioural effects induced in rats and chicks by D2 dopamine agonists. Physiol. Behav., 1993, 54, 695–700.
FERRARI F., PELLONI GIULIANI D.: Behavioural evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist. Psychopharmacology, 1993, 113: 172–176.
FERRARI F., GIULIANI D.: The selective D2 dopamine receptor antagonist eticlopride counteracts the ejaculatio praecox induced by the selective D2 dopamine agonist SND 919 in the rat. Life Sci., 1994, 55: 1155–1162.
FERRAZ M.R., SANTOS R.: Amantadine stimulates sexual behavior in male rats. Pharmacol. Biochem. Behav., 1995, 51: 709–714.
FERRAZ M.R., FERRAZ M.M., SANTOS R.: How REM sleep deprivation and amantadine affect male rat sexual behavior. Pharmacol. Biochem. Behav., 2001, 69: 325–332.
FUMERO B., FERNANDEZ-VERA J.R., GONZALEZ-MORA J.L., MAS M.: Changes in monoamine turnover in forebrain areas associated with masculine sexual behavior: a microdialysis study. Brain Res., 1994, 662: 233–239.
GISOLFI C.V., MOAR F., WALL P.T.: Dopamine and temperature regulation in the primate: effects of apomorphine and pimozide. Brain Res. Bull., 1980, 5: 349–352.
GITLIN M.J.: Effects of depression and antidepressants on sexual functioning. Bull. Menninger. Clin., 1995, 59: 232–248.
GIULIANI D., FERRARI F.: Differential behavioral response to dopamine D2 agonists by sexually naïve, sexually active, and sexually inactive male rats. Behav. Neurosci., 1996, 110: 802–808.
GIULIANO F., RAMPIN O. McKENNA K.: Animal models used in the study of erectile dysfunction. In: CC Carson III, RS Kirby, I Goldstein eds. Textbook of erectile dysfunction, Oxford, ISIS Medical Media, 1999: chapt. 5, 43–49.
GIULIANO F., ALLARD J., RAMPIN O. et al.: Spinal proerectile effect of apomorphine in the anesthetized rat. Int. J. Impotence Res., 2001, 13: 110–115.
GIULIANO F., ALLARD J., RAMPIN O. et al.: Pro-erectile effect of systemic apomorphine: existence of a spinal site of action. J. Urol., 2002, 167: 402–406.
GIULIANO F., ALLARD J.: Dopamine and male sexual function. Eur. Urol., 2001, 40: 601–608.
GOLDSTEIN I., CARSON C., ROSEN R., ISLAM A.: Vasomax for the treatment of male erectile dysfunction. World J. Urol., 2001, 19: 51–56.
GOLDSTEIN I., LUE T.F., PADMA-NATHAN H., ROSEN R.C., STEERS W.D., WICKER P.A.: Oral sildenafil in the treatment of erectile dysfunction. New Engl. J. Med., 1998, 338: 1397–1404.
HEATON J.P.W., VARRIN S.J., MORALES A.: The characterization of a bio-assay of erectile function in a rat model. J. Urol., 1991, 145: 1099–1102.
HEATON J.P.W., VARRIN S.J.: Metoclopramide decreases apomorphine-induced yawning and penile erection. Pharmacol. Biochem. Behav., 1991, 38: 917–920.
HEATON J.P.W., VARRIN S.J.: Effects of castration and exogenous testosterone supplementation in an animal model of penile erection. J. Urol., 1994, 151: 797–800.
HEATON J.P.W., MORALES A., ADAMS M.A., JOHNSTON B., EL-RASHIDY R.: Recovery of erectile function by the oral administration of apomorphine. Urol., 1995, 45: 200–206.
HEATON J.P.W.: Key issues from the clinical trials of apomorphine SL. World J. Urol., 2001, 19: 25–31.
HEATON J.P., DEAN J., SLEEP D.J.: Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int. J. Impot. Res., 2002, 14: 61–64.
HOLMGREN B., URBA-HOLMGREN R., TRUCIOS N., ZERMENO M., EGUIBAR J.R.: Association of spontaneous and dopaminergic-induced yawning and penile erections in rat. Pharmacol. Biochem. Behav., 1985, 22: 31–35.
HORITA H., SATO Y., ADACHI H. et al.: T. Effects of levodopa on nocturnal penile tumescence: a preliminary study. J. Androl., 1998, 19: 619–624.
HULL E.M., BITRAN D., PEHEK E.A., WARNER R.K., BAND L.C., HOLMES G.M.: Dopaminergic control of male sex behavior in rats: effects of an intracerebrally-infused agonist. Brain Res., 1986, 370: 73–81.
HULL E.M., BAZZETT T.J., WARNER R.K., EATON R.C., THOMPSON J.T.: Dopamine receptors in the ventral tegmental area modulate male sexual behavior in rats. Brain Res., 1990, 512: 1–6.
HULL E.M., EATON R.C., MARKOWSKI V.P., MOSES J., LUMLEY L.A., JOUCKS J.A.: Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes. Implication for copulation. Life Sci., 1992, 51: 1705–1713.
HULL E.M., DU J., LORRAIN D.S., MATUSZEWICH L.: Extracellular dopamine in the medial, preoptic area: implications for sexual motivation and hormonal control of copulation. J. Neurosci., 1995, 15: 7465–7471.
HULL E.M., LORRAIN D.S., DU J. et al.: Hormone-neurotransmitter interactions in the control of sexual behavior. Behav. Brain Res., 1999, 105: 105–116.
HYYPPA M., RINNE U.K., SONNINEN V.: The activating effect of L-DOPA treatment on sexual functions and its experimental background. Acta Neurol. Scand. Suppl., 1970, 43: 223–224.
ISHIZUKA O., MATTIASSON A., STEERS W.D., ANDERSSON K.E.: Effects of spinal alpha-1 adrenoceptor antagonism on bladder activity induced by apomorphine in conscious rats with and without bladder outlet obstruction. Neurourol. Urodyn., 1997, 16: 191–200.
ISHIZUKA O., PANDITA R.K., MATTIASSON A., STEERS W.D., ANDERSSON K.E.: Stimulation of bladder activity by volume, L-DOPA and capsaicin in normal conscious rats— effects of spinal alpha-1 adrenoceptor blockade. Naunyn Schmiedebergs Arch. Pharmacol., 1997, 335: 787–793.
KAPLAN J.M., HAO J., SODERSTEN P.: Apomorphine induces ejaculation in chronic decerebrate rats. Neurosci. Lett., 1991, 129: 205–208.
KIELY M.E., THAVUNDAYIL J.X., LAL S.: Effect of blood sampling on apomorphine-induced penile tumescence in erectile impotence: a case report. J. Psychiatry Neurosci., 20: 233–235.
LAL, S., ACKMAN D., THAVUNDAYIL J.X., KIELY M.E., ETIENNE P.: Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1984, 8: 695–699.
LAL S., LARYEA E., THAVUNDAYIL J.X.: Apomorphine-induced penile tumescence in impotent patients—preliminary findings. Prog. Neuro-psychopharmacol. Biol. Psychiatry, 1987, 11: 235–242.
LAL S., TESFAYE Y., THAVUNDAYIL J.X. et al.: Apomorphine: clinical studies on erectile impotence and yawning. Prog. Neuropsychopharmacol Biol. Psychiatry, 1989, 13: 329–339.
LAL S., KIELY M.E., THAVUNDAYIL J.X., STEWART J.D., ASSALIAN P., ACKMAN C.F.: Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: an open study. J. Psychiatry Neurosci., 1991, 16: 262–266.
MAEDA N., MATSUOKA N., YAMAGUCHI I.: Septohippocampal cholinergic pathway and penile erections induced by dopaminergic and cholinergic stimulants. Brain Res., 1990, 537: 163–168.
MAEDA N., MATSUOKA N., YAMAGUCHI I.: Role of the dopaminergic, serotonergic and cholinergic link in the expression of penile erection in rats. Jpn J. Pharmacol., 1994, 66: 59–66.
MALMNAS C.O.: Effects of LSD-25, clonidine and apomorphine on copulatory behavior in the male rat. Acta Physiol. Scand. Suppl., 1973, 395: 96–128.
MALMNAS C.O.: Monoamine precursors and copulatory behavior in the male rat. Acta Physiol. Scand. Suppl., 1973, 395: 47–68.
MATSUOKA N., MAEDA N., YAMAZAKI M., YAMAGUCHI I.: Brain somatostatin depletion by cysteamine attenuates the penile erection induced by serotonergic and dopaminergic, but not by cholinergic activation. Brain Res., 1996, 729: 132–136.
MATUSZEWICH L., LORRAIN D.S., HULL E.M.: Dopamine release in the medial preoptic area of female rats in response to hormonal manipulation and sexual activity. Behav. Neurosci., 2000, 114: 772–782.
McKENNA K.E.: Neural circuitry involved in sexual function. J. Spinal. Cord. Med., 2001, 24: 148–154.
MEISEL R.L., SACHS B.D.: The physiology of male sexual behavior. In: Knobil E., Neill J.D. eds. The Physiology of Reproduction. New York, Raven Press, 1994, volume 2: 3–106.
MELIS M.R., ARGIOLAS A., GESSA G.L.: Apomorphine-induced penile erection and yawning: site of action in the brain. Brain Res., 1987, 415: 98–104.
MELIS M.R., ARGIOLAS A., GESSA G.L.: Evidence that apomorphine induces penile erection and yawning by releasing oxytocin in the central nervous system. Eur. J. Pharmacol., 1989, 164: 565–570.
MELIS M.R., STANCAMPIANO R., ARGIOLAS A.: Hippocampal oxytocin mediates apomorphine-induced penile erection and yawning. Pharmacol. Biochem. Behav., 1992, 42: 61–66.
MELIS M.R., ARGIOLAS A.: Nitric oxide synthase inhibitors prevent apomorphine-and oxytocin-induced penile erection and yawning in male rats. Brain Res. Bull., 1993, 32: 71–74.
MELIS M.R., STANCAMPIANO R., ARGIOLAS A.,: Prevention by Ng-nitro-L-arginine methyl ester of apomorphine-and oxytocin-induced penile erection and yawning: site of action in the brain. Pharmacol. Biochem. Behav., 1994, 48: 799–804.
MELIS M.R., MAURI A., ARGIOLAS A.,: Apomorphine- and oxytocin-induced penile erection and yawning in intact and castrated male rats: effect of sexual steroids. Neuroendocrinology, 1994, 59: 349–354.
MELIS M.R., ARGIOLAS A.: Dopamine and sexual behavior. Neurosci. Biobehav. Rev., 1995, 19: 19–38.
MELIS M.R., SUCCU S., ARGIOLAS A.: Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Eur. J. Neurosci., 1996, 8: 2056–2063.
MELIS M.R., SUCCU S., IANNUCCI U., ARGIOLAS A.: Prevention by morphine of apomorphine—and oxytocin-induced penile erection and yawning: involvement of nitric oxide. Naunyn-Schmiedebergs Arch. Pharmacol., 1997, 335: 595–600.
MISSALE C., NASH S.R., ROBINSON S.W., JABER M., CARON M.G.: Dopamine receptors: from structure to function. Physiol. Rev., 1998, 78: 189–225.
MITCHELL J.B., STEWART J.: Effects of castration, steroid replacement, and sexual experience on mesolimbic dopamine and sexual behaviors in the male rat. Brain Res., 1989, 491: 116–127.
MULHALL J.P.: Sublingual apomorphine for the treatment of erectile dysfunction. Expert. Opin. Investig. Drugs, 2002, 11: 295–302.
NAKAYAMA H., NAKAYAMA T., CARNES C.A., STRAUCH S.M., HAMLIN R.L.: Electrophysiologic and hemodynamic effects of apomorphine in dogs. Toxicol. Appl. Pharmacol., 2001, 177: 157–161.
NAPOLI-FARRIS L., FRATTA W., GESSA G.L.: Stimulation of dopamine autoreceptors elicits “premature ejaculation” in rats. Pharmacol. Biochem. Behav., 1984, 20: 69–72.
NOUEL D., COSTENTIN J.: Inhibition of apomorphine-induced yawning and penile erection by neurotensin. Peptides, 1991, 12: 755–759.
O’SULLIVAN J.D., HUGHES A.J.: Apomorphine-induced penile erections in Parkinson’s disease. Mov. Disorders, 1998, 13: 536–539.
PAGLIETTI E., PELLEGRINI QUARANTOTTI B., MEREU G., GESSA G.L.: Apomorphine and L-DOPA lower ejaculation threshold in the male rat. Physiol. Behav., 1978, 20: 559–562.
PEHEK E.A., THOMPSON J.T., EATON R.C., BAZZETT T.J., HULL E.M.: Apomorphine and haloperidol, but not domperidone, affect penile reflexes in rats. Pharmacol. Biochem. Behav., 1988, 31: 201–208.
PEHEK E.A., THOMPSON J.T., HULL E.M.: The effects of intracranial administration of the dopamine agonist apomorphine on penile reflexes and seminal emission in the rat. Brain Res., 1989, 500: 325–332.
PFAUS J.G., PHILLIPS A.G.: Cholecystokinin facilitates ejaculation in male rats: blockade with proglumide and apomorphine. Eur. J. Pharmacol., 1987, 141: 331–338.
PFAUS J.G., DAMSMA G., NOMIKOS G.G. et al.: Sexual behavior enhances central dopamine transmission in the male rat. Brain Res., 1990, 530: 345–348.
PIERINI A.A., NUSIMOVICH B.: Male diabetic impotence: effects of dopaminergic agents. Arch. Androl., 1981, 6: 347–350.
PLEIM E.T., MATOCHIK J.A., BARFIELD R.J., AUERBACH S.B.: Correlation of dopamine release in the nucleus accumbens with masculine sexual behavior in rats. Brain Res., 1990, 524: 160–163.
POMERANTZ S.M.: Apomorphine facilitates male sexual behavior of rhesus monkeys. Pharmacol. Biochem. Behav., 1990, 35: 659–664.
POMERANTZ S.M.: Quinelorane (LY 163502), a D2 dopamine receptor agonist, acts centrally to facilitate penile erections of male rhesus monkeys. Pharmacol. Biochem. Behav., 1991, 39: 123–128.
PUTMAN S.K., DU J., SATO S., HULL E.M.: Testosterone restoration of copulatory behavior correlates with medial preoptic dopamine release in castrated male rats. Horm. Behav., 2001, 39: 216–224.
REHMAN J., CHRIST G., ALYSKEWYCZ M., KERR E., MELMAN A.: Experimental hyperprolactinemia in a rat model: alteration in centrally mediated neuroerectile mechanisms. Int. J. Impot. Res., 2000, 12: 23–32.
SACHS B.D.: Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal. Neurosci. Biobehav. Rev., 2000, 24: 541–560.
SATO F., AOKI H., NAKAMURA K., TAGUCHI M., AOKI T., YASUDA N.: Suppressive effects of chronic hyperprolactinemia on penile erection and yawning following administration of apomorphine to pituitary-transplanted rats. J. Androl., 1997, 18: 21–25.
SCALETTA L.L., HULL E.M.: Systemic or intracranial apomorphine increases copulation in long-term castrated male rats. Pharmacol. Biochem. Behav., 1990, 37: 471–475.
SCHLATTER E.K.E., LAL S.: Treatment of alcoholism with Dent’s oral apomorphine method. Quart. J. Stud. Alc., 1972, 33: 430–436.
SCHWAB R.S., AMADOR L.F., LETTVIN J.Y.: Apomorphine in parkinson’s disease. Trans. Am. Neurol. Assoc., 1951, 76: 251–253.
SEGRAVES R.T., BARI M., SEGRAVES K., SPIRNAK P.: Effect of apomorphine on penile tumescence in men with psychogenic impotence. J. Urol., 1991, 145: 1174–1175.
SERRA G., FRATTA W., COLLU M., NAPOLI-FARRIS L., GESSA G.L.: Cycloheximide prevents apomorphine-induced yawning, penile erection and genital grooming in rats. Eur. J. Pharmacol., 1983, 86: 279–282.
SERRA G., COLLU M., LODDO S., CELASCO G., GESSA G.L.: Hypophysectomy prevents yawning and penile erection but not hypomotility induced by apomorphine. Pharmacol. Biochem. Behav., 1983, 19: 917–919.
SIMON P., GUARDIOLA B., BIZOT-ESPIARD J., SCHIAVI P., COSTENTIN J.: 5-HT1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists. Psychopharmacology, 1992, 108: 47–50.
SOURKERS T.L.: Disorders of the basal ganglia. In: Qiegel G., Agranoff B., Albers R.W., Molinoff P. eds. Basic Neurochemistry, 4th edition. New-York, Raven Press, 1989: 811–825.
STEFANICK M.L., SMITH E.R., CLARK J.T., DAVIDSON J.M.: Effects of a potent dopamine receptor agonist, RDS-127, on penile reflexes and seminal emission in intact and spinally transected rats. Physiol. Behav., 1982, 29: 973–978.
SZCZYPKA M.S., ZHOU Q.Y., PALMITER R.D.: Dopamine-stimulated sexual behavior is testosterone dependent in mice. Behav. Neurosci., 1998, 112: 1229–1235.
TAGLIAMONTE A., FRATTA W. DELFIACCO M., GESSA G.L.: Evidence that brain dopamine stimulates copulatory behavior in male rats. Riv. Farm. Therap., 1973, 4: 177–181.
TAGLIAMONTE A., FRATTA W., GESSA G.L.: Aphrodisiac effect of L-DOPA and apomorphine in male sexually sluggish rats. Experientia, 1974, 30: 381–382.
TAGLIAMONTE A., FRATTA W., DELFIACCO M., GESSA G.L.: Possible stimulatory role of brain dopamine in the copulatory behavior of male rats. Pharmacol. Biochem. Behav., 1974, 2: 257–260.
TARCAN T., SIROKY M.B., PARK K., GOLDSTEIN I., AZADZOI K.M.: Systemic administration of apomorphine improves the hemodynamic mechanism of clitoral and vaginal engorgement in the rabbit. Int. J. Impotence Res., 2000, 12: 235–240.
UITTI R.J., TANNER C.M., RAJPUT A.H., GOETZ C.G., KLAWANS H.L., THIESSEN B.: Hypersexuality with antiparkinsonian therapy. Clin. Neuropharmacol., 1989, 12: 375–383.
VALEVSKI A., MODAI I., ZBARSKI E., ZEMISHLANY Z., WEIZMAN A.: Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin. Neuropharmacol., 1998, 21: 355–357.
VON KEITZ A.: The management of erectile dysfunction in the community. Int. J. Impotence Res., 2001, 13 Suppl 3: 45–51.
VON KEITZ A.T., STROBERG P., BUKOFZER S., MALLARD N., HIBBERD M.: A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. B.J.U. Int., 2002, 89: 409–415.
WERSINGER S.R., RISSMAN E.F.: Dopamine activates masculine sexual behavior independent of the estrogen receptor alpha. J. Neurosci., 2000, 20: 4248–4254.
WESSELLS H., FUCIARELLI K., HANSEN J. et al.: Synthetic melanotropic peptide initiates erection in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J. Urol., 1998, 160: 389–393.
YAMAGUCHI Y., KOBAYASHI H.: Effects of apomorphine, physostigmine and vasoactive intestinal polypeptide on penile erection and yawning in diabetic rats. Eur. J. Pharmacol., 1994, 254: 91–96.
YARYURA-TOBIAS J.A., DIAMOND B., MERLIS S.: The action of L-DOPA on schizophrenic patients; a preliminary report. Curr. Ther. Res., 1970, 12: 528–531.
YOUSSEF A.F., FORT F.L., RONSEN B., SCHROEDER R., WILLIAMS K., AULETTA C.: Evaluation of apomorphine HCl effects on reproductive endpoints: studies in male rats and dogs. Toxicol. Sci., 1999, 51: 273–279.
ZARRINDAST M.R., SHOKRAVI S., SAMINI M.: Opposite influence of dopaminergic receptor subtypes on penile erection. Gen. Pharmacol., 1992, 23: 671–675.
ZARRINDAST M.R., FARAHVASH H.: Effects of GABA-ergic drugs on penile erection induced by apomorphine in rats. Psychopharmacol., 1994, 115: 249–253.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rampin, O. Apomorphine, systèmes dopaminergiques centraux et contrôle de l’érection. Androl. 12, 156–166 (2002). https://doi.org/10.1007/BF03034962
Issue Date:
DOI: https://doi.org/10.1007/BF03034962